Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...
Apogee Therapeutics’ $483 Million Common Stock Offering
89bio Inc.’s $172 Million Upsized Public Offering
Gibson, Dunn & Crutcher LLP advised 89bio, Inc. on its upsized public offering. 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...